Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Administration of T Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch in Subjects With Lung Cancer

NCT05620342 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT05620342
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05620342 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Administration of T Cells Expressing a 2nd Generation GD2 Chimeric Antigen Receptor, IL-15, and iCaspase9 Safety Switch in Subjects With Lung Cancer
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
June 21, 2023
Completion date
October 24, 2029
Enrollment
24 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung cancer, non small cell lung cancer, small cell lung carcinoma